Rosuvastatin (Crestor) is associated with a 2.8-fold increased risk of lung cancer

This study was published in the Libyan Journal of Medicine 2012 Dec 27;7(0):1-3

 

Study title and authors:

Statins use and female lung cancer risk in Taiwan.

Lai SW, Liao KF, Lin CL, Sung FC, Cheng YH.

School of Medicine, China Medical University, Taichung, Taiwan; Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan.

 

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/23272648

This study investigated the assoiation between statins and lung cancer in women. The study included 1,117 women with newly diagnosed lung cancer, average age 66.5 years, who were compared to 4,468 age-matched women without lung cancer.

The study found:
(a) Statin use was associated with a 7% increased risk of lung cancer.
(b) Rosuvastatin (Crestor) use of over 12 months duration was associated with a 2.8-fold increased risk of lung cancer.

The data from the study reveals that statin use is associated with higher rates of lung cancer.